Compare Brown-Forman Corporation Class B (BF.B) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Revvity Inc — how do they compare? Brown-Forman Corporation Class B trades at $25.18, while Revvity Inc trades at $110.91 (market cap $12.41B). The key difference: Revvity Inc pays a 0.25% dividend while Brown-Forman Corporation Class B pays none, and Revvity Inc is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.
| BF.B | RVTY | |
|---|---|---|
Sector | Consumer Staples | Technology |
52-Week High | $31.26 | $117.75 |
52-Week Low | $22.80 | $82.26 |
Market Cap | — | $12.41B |
Enterprise Value | — | $14.90B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $26.25, up 0.31% on the day, with a bearish technical signal from moving averages but mixed oscillators. Recent earnings show three consecutive beats, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is divided, with a 25% buy rating amid cautious technical indicators.
The stock's outlook is balanced by strong earnings momentum against bearish technicals. Opportunities lie in continued earnings outperformance, while risks include weak technical trends and lack of consensus among analysts. Investors should weigh fundamental strength against near-term price pressure.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
